This important program features key industry interviews and news-style reports, along with sponsored editorial profiles. TauRx were invited to contribute to this program to explain their work in the field of neurodegenerative disease and the benefits of taking part in a clinical trial.
Professor Claude Wischik, CEO, says, “It was a pleasure to be part of this news-style program showcasing the latest developments in care, research and technology. The impact of dementia globally has been brought to focus once again by the devastating effects of the Covid-19 pandemic, and now, more than ever, the pharmaceutical industry needs to re-focus its efforts in finding new and effective ways to combat this disease. Our focus at TauRx has always been in the field of neurodegenerative disease and we hope that our contribution to this program will help highlight the progress of research and the importance of patients taking part in clinical trials.”
